Tarsus Pharmaceuticals (NASDAQ:TARS) Earns “Buy” Rating from Guggenheim

Guggenheim reaffirmed their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS) in a research report sent to investors on Monday morning,Benzinga reports.

A number of other research firms have also recently issued reports on TARS. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Barclays lifted their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Monday, January 27th. Finally, The Goldman Sachs Group lifted their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $56.00.

Tarsus Pharmaceuticals Price Performance

Shares of TARS opened at $52.33 on Monday. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -13.73 and a beta of 1.01. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The company has a 50 day moving average of $52.06 and a two-hundred day moving average of $41.30.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of TARS. Jennison Associates LLC raised its stake in shares of Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after acquiring an additional 698,712 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after buying an additional 420,057 shares in the last quarter. Ally Bridge Group NY LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at $10,587,000. Vestal Point Capital LP acquired a new stake in Tarsus Pharmaceuticals during the 3rd quarter worth $7,565,000. Finally, Ikarian Capital LLC boosted its stake in Tarsus Pharmaceuticals by 28.7% during the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock worth $33,886,000 after purchasing an additional 230,000 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.